Is the decreasing availability of vecuronium and pancuronium putting patients at risk?
Church
Hannah L
HL
Kong
K L
KL
North
Jonathan
J
D000707:Anaphylaxis / Q000517:prevention & control*; D003429:Cross Reactions / Q000276:immunology; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects; D003473:Neuromuscular Nondepolarizing Agents / Q000600:supply & distribution*; D010197:Pancuronium / Q000600:supply & distribution*; D014673:Vecuronium Bromide / Q000600:supply & distribution*
D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; D010197:Pancuronium